Folgen
Michael Kresken
Michael Kresken
Professor für Pharmakologie
Bestätigte E-Mail-Adresse bei antiinfectives-intelligence.de
Titel
Zitiert von
Zitiert von
Jahr
Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals
W Witte, M Kresken, C Braulke, C Cuny
Clinical Microbiology and Infection 3 (4), 414-422, 1997
1891997
Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of …
M Kresken, D Hafner, FJ Schmitz, TA Wichelhaus
International journal of antimicrobial agents 23 (6), 577-581, 2004
1352004
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin
M Kresken, B Wiedemann
Antimicrobial Agents and Chemotherapy 32 (8), 1285-1288, 1988
1291988
Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975-1995
M Kresken, D Hafner, SGBR the Paul-Ehrlich Society for Chemotherapy:
Infection 27 (suppl 2), 2-8, 1999
109*1999
The epidemiology of β-lactamases
B Wiedemann, C Kliebe, M Kresken
Journal of Antimicrobial Chemotherapy 24 (suppl_B), 1-22, 1989
971989
Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005–2009)
X Schleicher, PG Higgins, H Wisplinghoff, B Körber-Irrgang, M Kresken, ...
Clinical Microbiology and Infection 19 (8), 737-742, 2013
932013
Antimicrobial Resistance and Type Distribution of Streptococcus pneumoniae Isolates Causing Systemic Infections in Germany, 1992–1994
RR Reinert, A Queck, A Kaufhold, M Kresken, R Lütticken
Clinical Infectious Diseases 21 (6), 1398-1401, 1995
911995
Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum
M Kresken, D Hafner, FJ Schmitz, TAS Wichelhaus
84*2007
Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa
M Kresken, D Hafner
Chemotherapie Journal 5, 225-230, 1996
721996
Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum
M Kresken, D Hafner, FJ Schmitz, TAS Wichelhaus
Bericht über die Ergebnisse einer multizentrischen Studie der …, 2001
712001
Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin
C von Eiff, RR Reinert, M Kresken, J Brauers, D Hafner, G Peters
Journal of clinical microbiology 38 (8), 2819-2823, 2000
712000
Rationaler Einsatz oraler Antibiotika bei Erwachsenen: Empfehlungen einer Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V.
F VOGEL, H SCHOLZ, B Al-Nawas, W Elies, M Kresken, H Lode, O Müller, ...
Medizinische Monatsschrift für Pharmazeuten 25 (6), 193-204, 2002
69*2002
Prevalence of fluoroquinolone resistance in Europe
M Kresken, D Hafner, B Wiedemann, H Mittermayer, L Verbist, ...
Infection 22 (2), S90-S98, 1994
691994
In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions
W Stubbings, P Leow, GC Yong, F Goh, B Körber-Irrgang, M Kresken, ...
Antimicrobial agents and chemotherapy 55 (9), 4394-4397, 2011
642011
Changing Pattern of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus From German Hospitals
W Witte, C Braulke, C Cuny, D Heuck, M Kresken
Infection Control & Hospital Epidemiology 22 (11), 683-686, 2001
612001
Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers
FME Wagenlehner, F Münch, A Pilatz, B Bärmann, W Weidner, ...
Antimicrobial agents and chemotherapy 58 (2), 713-721, 2014
602014
Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa
M Kresken, D Hafner
Chemother J 9 (2), 51-86, 2000
602000
Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries
M Kresken, B Körber-Irrgang, DJ Biedenbach, N Batista, V Besard, ...
Clinical Microbiology and Infection 22 (1), 63. e1-63. e5, 2016
592016
Antimikrobielle Therapie der Sepsis
KF Bodmann, F Vogel, W Graninger, M Kresken, WD Paar, G Peters, ...
Chemotherapie Journal 10 (2), 43-55, 2001
592001
Activities of various β-lactams and β-lactam/β-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains
J Brauers, U Frank, M Kresken, AC Rodloff, H Seifert
Clinical microbiology and infection 11 (1), 24-30, 2005
572005
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20